Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-Guided Therapy of Aggressive Non-Hodgkin's Lymphomas (PETAL)
NCT00554164Phase 3Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Nov 2007
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, methotrexate, ifosfamide, etoposide, cytarabine in non-Hodgkin lymphoma (NHL), sponsored by Universitätsmedizin Essen. Started Nov 2007; status: completed.
02
Drugs
rituximabmethotrexateifosfamideetoposidecytarabine
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00554164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00554164.